Ascendis Pharma Gets FDA Letter Noting Deficiencies in TransCon PTH's New Drug App
By Chris Wack
Ascendis Pharma A/S said Monday that the U.S. Food & Drug Administration has found deficiencies in the company's new drug application for TransCon PTH, its candidate for the treatment of hypoparathyroidism.
According to the Copenhagen-based biopharmaceutical company, the FDA letter didn't disclose the deficiencies and precludes them from holding further discussions about labeling and post-marketing requirements and commitments at this time. However, Ascendis said, the FDA also stated that the letter didn't reflect a final regulatory decision on the new drug application.
Ascendis shares were halted at $107.22 in premarket trading Monday.
Ascendis said that to date, 145 out of 154 clinical trial participants continue to be treated with TransCon PTH in Phase 2 and Phase 3 clinical trial open label extensions. In these studies, TransCon PTH has been generally well-tolerated, with no discontinuations related to the study drug, according to Ascendis.
In December, the FDA allowed Ascendis to initiate a U.S. Expanded Access Program for TransCon PTH in eligible adults with hypoparathyroidism previously treated with parathyroid hormone. The EAP, which remains open for enrollment, gives U.S. physicians the opportunity to request access to investigational TransCon PTH for eligible patients.
In Europe, Ascendis has received a comprehensive Day-120 response from the European Medicines Agency. Ascendis said it remains on track for TransCon PTH receiving a European Commission decision on a marketing authorization application during the fourth quarter this year.
If approved, Ascendis expects TransCon PTH to see its first European country launch in early next year.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
April 03, 2023 07:51 ET (11:51 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
5 Stocks to Buy That We Still Like After They’ve Run Up
-
Markets Brief: Stocks Are Starting to Look Cheap Again
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track
-
American Airlines Earnings: We See Costs Overshadowing Market Share This Year
-
Snap Earnings: Advertising Growth and Snapchat+ Drive Monetization
-
STMicro Earnings: We Still See an Attractive Margin of Safety Despite a Poor First-Half Forecast
-
Alphabet Shares Surge on Strong Earnings, Dividend Surprise
-
Microsoft Earnings: Firm Beats Forecasts on Strong AI and Cloud Demand
-
PG&E Earnings: Near-Term Regulatory Certainty Supports Industry-Leading Earnings Growth